Barinthus Bio amends 8-K to correct VTP-850 trial statement; reports Q2 net loss of $21.1M

Barinthus Biotherapeutics plc.

2025-Q2 EPS reported -$1.01

Net loss $21.1M ($0.52/share) vs $19.7M ($0.49/share) in Q1 2025.
Cash $87.8M, down $12.8M from Q1; runway unchanged into 2027.
R&D expense $8.0M, down from $8.3M; G&A $15.4M, up from $12.6M.
VTP-1000 AVALON MAD initiated, SAD data due early Q4 2025.
Correction: Previous inaccurate sub-bullet on VTP-850 trial result replaced; trial complete, well tolerated, immunogenicity signs.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.